{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T23:11:37Z","timestamp":1792883497506,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2015,7,19]],"date-time":"2015-07-19T00:00:00Z","timestamp":1437264000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1007\/s40264-015-0327-3","type":"journal-article","created":{"date-parts":[[2015,7,18]],"date-time":"2015-07-18T01:51:18Z","timestamp":1437184278000},"page":"1103-1113","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":179,"title":["Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database"],"prefix":"10.1007","volume":"38","author":[{"given":"Paul B.","family":"Watkins","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Kaplowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David H.","family":"Alpers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaime D.","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan M.","family":"Smotzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holly","family":"Krasa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vicente E.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank S.","family":"Czerwiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher A.","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,7,19]]},"reference":[{"issue":"14","key":"327_CR1","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","volume":"359","author":"JJ Grantham","year":"2008","unstructured":"Grantham JJ. Clinical practice. Autosomal dominant polycystic kidney disease. N Engl J Med. 2008;359(14):1477\u201385.","journal-title":"N Engl J Med."},{"issue":"9569","key":"327_CR2","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","volume":"369","author":"VE Torres","year":"2007","unstructured":"Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287\u2013301.","journal-title":"Lancet."},{"issue":"10","key":"327_CR3","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","volume":"7","author":"JJ Grantham","year":"2011","unstructured":"Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol. 2011;7(10):556\u201366.","journal-title":"Nat Rev Nephrol."},{"key":"327_CR4","unstructured":"United States Renal Data System. 2014 annual data report: an overview of the epidemiology of kidney disease in the United States. Bethesda: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2014."},{"issue":"6","key":"327_CR5","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1046\/j.1523-1755.2003.00023.x","volume":"63","author":"T Yamaguchi","year":"2003","unstructured":"Yamaguchi T, Nagao S, Wallace DP, Belibi FA, Cowley BD, Pelling JC, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney Int. 2003;63(6):1983\u201394.","journal-title":"Kidney Int."},{"issue":"7","key":"327_CR6","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1681\/ASN.V1171179","volume":"11","author":"K Hanaoka","year":"2000","unstructured":"Hanaoka K, Guggino WB. cAMP regulates cell proliferation and cyst formation in autosomal polycystic kidney disease cells. J Am Soc Nephrol. 2000;11(7):1179\u201387.","journal-title":"J Am Soc Nephrol."},{"issue":"10","key":"327_CR7","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VH Gattone 2nd","year":"2003","unstructured":"Gattone VH 2nd, Wang X, Harris PC, Torres VE. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med. 2003;9(10):1323\u20136.","journal-title":"Nat Med."},{"issue":"4","key":"327_CR8","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/nm1004","volume":"10","author":"VE Torres","year":"2004","unstructured":"Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH 2nd. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med. 2004;10(4):363\u20134.","journal-title":"Nat Med."},{"issue":"25","key":"327_CR9","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367(25):2407\u201318.","journal-title":"N Engl J Med."},{"issue":"3","key":"327_CR10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2165\/11586600-000000000-00000","volume":"34","author":"PB Watkins","year":"2011","unstructured":"Watkins PB, Desai M, Berkowitz SD, Peters G, Horsmans Y, Larrey D, et al. Evaluation of drug-induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. Drug Saf. 2011;34(3):243\u201352.","journal-title":"Drug Saf."},{"key":"327_CR11","unstructured":"United States Food and Drug Administration. Guidance for industry, drug-induced liver injury: premarketing clinical evaluation. 2014. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM174090.pdf . Accessed 11 Feb 2015."},{"issue":"3","key":"327_CR12","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/clpt.2008.262","volume":"85","author":"JR Senior","year":"2009","unstructured":"Senior JR. Monitoring for hepatotoxicity: what is the predictive value of liver \u201cfunction\u201d tests? Clin Pharmacol Ther. 2009;85(3):331\u20134.","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 1","key":"327_CR13","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1007\/s40264-014-0185-4","volume":"37","author":"A Regev","year":"2014","unstructured":"Regev A, Seeff L, Merz M, Ormarsdottir S, Aithal GP, Gallivan J, et al. Causality assessment for suspected DILI during clinical phases of drug development. Drug Saf. 2014;37(Suppl 1):S47\u201356.","journal-title":"Drug Saf."},{"issue":"6","key":"327_CR14","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, Freston J, Chalasani N, Bonacini M, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51(6):2117\u201326.","journal-title":"Hepatology."},{"issue":"1","key":"327_CR15","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2165\/00002018-200932010-00005","volume":"32","author":"RJ Fontana","year":"2009","unstructured":"Fontana RJ, Watkins PB, Bonkovsky HL, Chalasani N, Davern T, Serrano J, et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009;32(1):55\u201368.","journal-title":"Drug Saf."},{"key":"327_CR16","unstructured":"Augmentin [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2006."},{"key":"327_CR17","doi-asserted-by":"crossref","unstructured":"Teschke R, Frenzel C. Drug induced liver injury: do we still need a routine liver biopsy for diagnosis today? Ann Hepatol. 2013\u20132014;13(1):121\u20136.","DOI":"10.1016\/S1665-2681(19)30913-5"},{"issue":"6","key":"327_CR18","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1200\/JCO.2010.31.3197","volume":"29","author":"CF Spraggs","year":"2011","unstructured":"Spraggs CF, Budde LR, Briley LP, Bing N, Cox CJ, King KS, et al. HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer. J Clin Oncol. 2011;29(6):667\u201373.","journal-title":"J Clin Oncol."},{"issue":"8","key":"327_CR19","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/ng.632","volume":"42","author":"JB Singer","year":"2010","unstructured":"Singer JB, Lewitzky S, Leroy E, Yang F, Zhao X, Klickstein L, et al. A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury. Nat Genet. 2010;42(8):711\u20134.","journal-title":"Nat Genet."},{"issue":"3","key":"327_CR20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/sj.tpj.6500458","volume":"8","author":"A Kindmark","year":"2008","unstructured":"Kindmark A, Jawaid A, Harbron CG, Barratt BJ, Bengtsson OF, Andersson TB, et al. Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis. Pharmacogenomics J. 2008;8(3):186\u201395.","journal-title":"Pharmacogenomics J."},{"issue":"1","key":"327_CR21","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cgh.2014.07.051","volume":"13","author":"MC Hogan","year":"2015","unstructured":"Hogan MC, Abebe K, Torres VE, Chapman AB, Bae KT, Tao C, et al. Liver involvement in early autosomal-dominant polycystic kidney disease. Clin Gastoenterol Hepatol. 2015;13(1):155\u201364.","journal-title":"Clin Gastoenterol Hepatol."},{"issue":"1","key":"327_CR22","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2215\/CJN.00080605","volume":"1","author":"KT Bae","year":"2006","unstructured":"Bae KT, Zhu F, Chapman AB, Torres VE, Grantham JJ, Guay-Woodford LM, et al. Magnetic resonance imaging evaluation of hepatic cysts in early autosomal-dominant polycystic kidney disease: the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease cohort. Clin J Am Soc Nephrol. 2006;1(1):64\u20139.","journal-title":"Clin J Am Soc Nephrol."},{"issue":"2","key":"327_CR23","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/ng0695-151","volume":"10","author":"J Hughes","year":"1995","unstructured":"Hughes J, Ward CJ, Peral B, Aspinwall R, Clark K, San Millan JL, et al. The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains. Nat Genet. 1995;10(2):151\u201360.","journal-title":"Nat Genet."},{"key":"327_CR24","unstructured":"Otsuka Pharmaceutical Development & Commercialization, Inc. Tolvaptan phase 3 efficacy and safety study in ADPKD (TEMPO3\/4) [ClinicalTrials.gov identifier NCT00428948]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 8 Jul 2015."},{"key":"327_CR25","unstructured":"Otsuka Pharmaceutical Development & Commercialization, Inc. Open-label tolvaptan study in subjects with ADPKD (TEMPO 4\/4) [ClinicalTrials.gov identifier NCT01214421]. US National Institutes of Health, ClinicalTrials.gov. http:\/\/www.clinicaltrials.gov . Accessed 8 Jul 2015."}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40264-015-0327-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0327-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-015-0327-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,18]],"date-time":"2022-05-18T09:37:31Z","timestamp":1652866651000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40264-015-0327-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7,19]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["327"],"URL":"https:\/\/doi.org\/10.1007\/s40264-015-0327-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,7,19]]}}}